Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab in Eosinophilic Esophagitis
NCT03656380Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Mar 2019
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing Mepolizumab 300 mg with Placebo / Mepolizumab 100 mg (2 arms). Primary endpoint: Mean Change in Dysphagia Score (EEsAI) at 3 months. Started Mar 2019; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT03656380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03656380.